Presidio Pharmaceuticals, Inc. to Present at BioInvestor Forum Conference, 2009

SAN FRANCISCO--(BUSINESS WIRE)--Presidio Pharmaceuticals, Inc. announced today that Dr. Omar K. Haffar, President and Chief Executive Officer, will present an update on Presidio’s drug development activities at the BioInvestor Forum Conference on October 29, 2009 at 11:00AM in the Presidio Room at the Palace Hotel, San Francisco. The conference is being held October 28-29, 2009.

About Presidio

Presidio Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the discovery, in-licensing, development and commercialization of novel therapeutics for viral infections, including HIV and HCV. For more information, please visit our website at: www.presidiopharma.com.

Contacts

Presidio Pharmaceuticals
Omar K. Haffar, PhD, 415-655-7561
omar@presidiopharma.com

Recent Stories from Presidio Pharmaceuticals, Inc.

Presidio Pharmaceuticals Reports Progress with Hepatitis C Antiviral Programs

January 09, 2012

SAN FRANCISCO--(BUSINESS WIRE)--Presidio Pharmaceuticals, Inc. announced today the successful completion of a Phase 1a dose-ranging assessment of PPI-668, a potent, pan-genotypic second-generation ... more »
Presidio Pharmaceuticals, Inc. Announces Clinical Proof-of-Concept Data for its First HCV NS5A Inhibitor, PPI-461, and Initiation of Clinical Testing for its Second-Generation NS5A Inhibitor, PPI-668.

November 04, 2011

SAN FRANCISCO--(BUSINESS WIRE)--Presidio Pharmaceuticals, Inc. today announced progress with its HCV antiviral drug discovery and development programs. A primary company objective is to advance mul... more »
Presidio Pharmaceuticals, Inc. Announces the Appointment of H. Daniel Perez, M.D. as President and Chief Executive Officer

October 25, 2011

SAN FRANCISCO--(BUSINESS WIRE)--Presidio Pharmaceuticals, Inc. is pleased to announce that the Company's Board of Directors has appointed Dr. H. Daniel Perez to be its new President and CEO, replac... more »